Alexandra J. Lansky

Alexandra J. Lansky

Auto-generated profile, based on publicly available information

Alexandra J. Lansky

Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2020 in European Heart Journal
Verified
Journal Article
Open access
PDF file
VKVijay Kunadian
Vijay Kunadian
ACAlaide Chieffo
Alaide Chieffo
PCPaolo G Camici
Paolo G Camici
CBColin Berry
Colin Berry
JEJavier Escaned
Javier Escaned
ABAndreas Baumbach
Andreas Baumbach
This consensus document, a summary of the views of an expert panel organized by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), appraises the importance of ischaemia with non-obstructive coronary arteries (INOCA). Angina pectoris affects approximately 112 million people globally. Up to 70% of patients undergoing invasive angiography do not have obstructive coronary artery disease, more common in women than in men, and a large proportion have INOCA as a cause of their symptoms. INOCA patients present with a wide spectrum of symptoms and signs that are often misdiagnosed as non-cardiac leading to under-diagnosis/investigation and under-treatment. INOCA can result from heterogeneous mechanism including coronary vasospasm and microvascular dysfunction and is not a benign condition. Compared to asymptomatic individuals, INOCA is associated with increased incidence of cardiovascular events, repeated hospital admissions, as well as impaired quality of life and associated increased health care costs. This consensus document provides a definition of INOCA and guidance to the community on the diagnostic approach and management of INOCA based on existing evidence from research and best available clinical practice; noting gaps in knowledge and potential areas for further investigation.

19 May 2015 in European Heart Journal
Verified
Journal Article
Open access
PDF file
ALAlexandra J. Lansky
Alexandra J. Lansky
JSJoachim Schofer
Joachim Schofer
DTDidier Tchetche
Didier Tchetche
PSPieter Stella
Pieter Stella
CPCody G. Pietras
Cody G. Pietras
ABAndreas Baumbach
Andreas Baumbach
To evaluate the safety, efficacy, and performance of the TriGuard™ HDH Embolic Deflection Device (TriGuard) compared with no cerebral protection in patients undergoing transcatheter aortic valve implantation (TAVI). From February 2014 to March 2015, 85 subjects undergoing TAVI at 13 centres in Europe and Israel were randomized to TriGuard protection vs. no protection. Subjects underwent neurologic and cognitive evaluation at baseline, pre-discharge and 30 days; cerebral diffusion-weighted magnetic resonance imaging was performed at 4 ± 2 days post-procedure and at 30 days. Technical success, which included complete 3-vessel cerebral coverage, was achieved in 88.9% (40/45) of cases. The primary in-hospital procedural safety endpoint (death, stroke, life-threatening or disabling bleeding, stage 2 or 3 acute kidney injury, or major vascular complications) occurred in 21.7% of TriGuard and 30.8% of control subjects (P = 0.34). In the Per Treatment population (subjects with complete three-vessel cerebral coverage), TriGuard use was associated with greater freedom from new ischaemic brain lesions (26.9 vs. 11.5%), fewer new neurologic deficits detected by the National Institutes of Health Stroke Scale (3.1 vs. 15.4%), improved Montreal Cognitive Assessment (MoCA) scores, better performance on a delayed memory task (P = 0.028) at discharge, and a >2-fold increase in recovery of normal cognitive function (MoCA score >26) at 30 days. TriGuard cerebral protection during TAVI is safe and complete cerebral vessel coverage was achieved in 89% of subjects. In this exploratory study, subjects undergoing protected TAVI had more freedom from ischaemic brain lesions, fewer neurologic deficits, and improved cognitive function in some domains at discharge and 30 days compared with controls.

1 March 2012 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
ALAlexandra J. Lansky
Alexandra J. Lansky
VNVivian G. Ng
Vivian G. Ng
AMAkiko Maehara
Akiko Maehara
GWGiora Weisz
Giora Weisz
ALAmir Lerman
Amir Lerman
GSGregg W. Stone
Gregg W. Stone

10 March 2014 in BMC Medicine
Verified
Journal Article
Open access
PDF file
GFGeorg M Fröhlich
Georg M Fröhlich
ALAlexandra J Lansky
Alexandra J Lansky
JWJohn Webb
John Webb
MRMarco Roffi
Marco Roffi
STStefan Toggweiler
Stefan Toggweiler
PMPascal Meier
Pascal Meier
The hypothesis of this study was that local anesthesia with monitored anesthesia care (MAC) is not harmful in comparison to general anesthesia (GA) for patients undergoing Transcatheter Aortic Valve Implantation (TAVR).

1 February 2017 in JACC
Verified
Journal Article
Closed access
ALAlexandra J. Lansky
Alexandra J. Lansky
SMSteven R. Messé
Steven R. Messé
ABAdam M. Brickman
Adam M. Brickman
MDMichael Dwyer
Michael Dwyer
HWH. Bart van der Worp
H. Bart van der Worp
ABAndreas Baumbach
Andreas Baumbach

1 December 2010 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
ALAlexandra J. Lansky
Alexandra J. Lansky
GSGregg W. Stone
Gregg W. Stone